Patents by Inventor David Robert Perkins

David Robert Perkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,3,4-thiadiazole compounds and their use in treating cancer
    Patent number: 10040789
    Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, is described. Q can be pyridazin-3-yl, 6-fluoropyridazin-3-yl; R1 can be H; R2 and R3 can each independently be C1-C6 alkyl, or R2 and R3 taken together are —(CH2)3—; or R1 and R2 taken together can be —(CH2)2— and R3 can be —CH3; R4 halo, —CH3, —OCH3, —OCHF2, —OCF3, or —CN; and n can be 0, 1, or 2. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: August 7, 2018
    Assignees: AstraZeneca AB, Cancer Research Technology Limited
    Inventors: David Robert Perkins, Maurice Raymond Verschoyle Finlay, Johannes Wilhelmus Maria Nissink, Piotr Antoni Raubo, Peter Duncan Smith, Andrew Bailey
  • 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer
    Publication number: 20170333429
    Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, is described. Q can be pyridazin-3-yl, 6-fluoropyridazin-3-yl; R1 can be H; R2 and R3 can each independently be C1-C6 alkyl, or R2 and R3 taken together are —(CH2)3—; or R1 and R2 taken together can be —(CH2)2— and R3 can be —CH3; R4 halo, —CH3, —OCH3, —OCHF2, —OCF3, or —CN; and n can be 0, 1, or 2. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
    Type: Application
    Filed: November 29, 2016
    Publication date: November 23, 2017
    Applicants: AstraZeneca AB, Cancer Research Technology Limited
    Inventors: David Robert Perkins, Maurice Raymond Verschoyle Finlay, Johannes Wilhelmus Maria Nissink, Piotr Antoni Raubo, Peter Duncan Smith, Andrew Bailey